Emerging monoclonal antibody therapies for malignant gliomas

Bibliography

• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and ras signaling pathways. Expert Rev. Anticancer Ther. (2003) 3(5):595-614.
   PubMedGoogle Scholar
• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. (2004) 4(1):105-128.
   PubMedGoogle Scholar
• KONDO Y, HOLLINGSWORTH EF, KONDO S: Molecular targeting for malignant gliomas (review). Int. J. Oncol. (2004) 24(5):1101-1109.
   PubMed Web of Science ®Google Scholar
• BOSKOVITZ A, WIKSTRAND CJ, KUAN CT, ZALUTSKY MR, REARDON DA, BIGNER DD: Monoclonal antibodies for brain tumour treatment. Expert Opin. Biol. Ther. (2004) 4(9):1453-1471.
   Google Scholar
• BUTOWSKI N, CHANG SM: Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control (2005) 12(2):116-124.
   PubMedGoogle Scholar
• MISCHEL PS, CLOUGHESY TF: Targeted molecular therapy of GBM. Brain Pathol. (2003) 13(1):52-61.
   PubMed Web of Science ®Google Scholar
• REARDON DA, WEN PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist (2006) 11(2):152-164.
   PubMed Web of Science ®Google Scholar
• PRASAD G, WANG H, HILL DL, ZHANG R: Recent advances in experimental molecular therapeutics for malignant gliomas. Curr. Med. Chem. Anticancer Agents (2004) 4(4):347-361.
   Google Scholar
• TANNER JE: Designing antibodies for oncology. Cancer Metastasis Rev. (2005) 24(4):585-598.
   PubMed Web of Science ®Google Scholar
• HOPKIN M: Can super-antibody drugs be tamed? Nature (2006) 240:855-856.
   Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1(2):118-129.
   PubMed Web of Science ®Google Scholar
• REARDON DA, AKABANI G, COLEMAN RE et al.: Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2002) 20(5):1389-1397.
   Google Scholar
• WERSALL P, OHLSSON I, BIBERFELD P et al.: Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother. (1997) 44(3):157-164.
   Google Scholar
• RIVA P, ARISTA A, FRANCESCHI G et al.: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. (1995) 55(Suppl. 23):5952s-5956s.
   PubMed Web of Science ®Google Scholar
• DAN MD, SCHLACHTA CM, GUY J et al.: Human antiglioma monoclonal antibodies from patients with astrocytic tumors. J. Neurosurg. (1992) 76(4):660-669.
   PubMed Web of Science ®Google Scholar
• WU AM, SENTER PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. (2005) 23(9):1137-1146.
   PubMed Web of Science ®Google Scholar
• GOETZ CM, RACHINGER W, DECKER M et al.: Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol. Immunother. (2005) 54(4):337-344.
   Google Scholar
• COLCHER D, PAVLINKOVA G, BERESFORD G, BOOTH BJ, CHOUDHURY A, BATRA SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. QJ Nucl. Med. (1998) 42(4):225-241.
   PubMedGoogle Scholar
• MARTENS T, SCHMIDT NO, ECKERICH C et al.: A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. (2006) 12(20 Part 1):6144-6152.
   Google Scholar
• MAMOT C, DRUMMOND DC, NOBLE CO et al.: Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. (2005) 65(24):11631-11638.
   PubMed Web of Science ®Google Scholar
• ZALUTSKY MR, MOSELEY RP, BENJAMIN JC et al.: Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. (1990) 50(13):4105-4110.
   PubMed Web of Science ®Google Scholar
• REIST CJ, ARCHER GE, WIKSTRAND CJ, BIGNER DD, ZALUTSKY MR: Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. (1997) 57(8):1510-1515.
   PubMed Web of Science ®Google Scholar
• LEE SW, FRAASS BA, MARSH LH et al.: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. (1999) 43(1):79-88.
   Web of Science ®Google Scholar
• HOPKINS K, CHANDLER C, EATOUGH J, MOSS T, KEMSHEAD JT: Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40(4):835-844.
   Web of Science ®Google Scholar
• LAMBERT JM: Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. (2005) 5(5):543-549.
   Web of Science ®Google Scholar
• SCHAEDEL O, REITER Y: Antibodies and their fragments as anti-cancer agents. Curr. Pharm. Des. (2006) 12(3):363-378.
   Web of Science ®Google Scholar
• RUSTAMZADEH E, LOW WC, VALLERA DA, HALL WA: Immunotoxin therapy for CNS tumor. J. Neurooncol. (2003) 64(1-2):101-116.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, ADACHI K, YAMAGUCHI F, TERAMOTO A: Experimental treatment of malignant gliomas with human monoclonal antibody–drug conjugates. Anticancer Res. (1999) 19(5B):4151-4155.
   PubMed Web of Science ®Google Scholar
• WU G, BARTH RF, YANG W, KAWABATA S, ZHANG L, GREEN-CHURCH K: Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. (2006) 5(1):52-59.
   PubMed Web of Science ®Google Scholar
• LASKE DW, ILERCIL O, AKBASAK A, YOULE RJ, OLDFIELD EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. (1994) 80(3):520-526.
   PubMed Web of Science ®Google Scholar
• FOEHR ED, LORENTE G, KUO J, RAM R, NIKOLICH K, URFER R: Targeting of the receptor protein tyrosine phosphatase β with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. (2006) 66(4):2271-2278.
   PubMed Web of Science ®Google Scholar
• MAMOT C, DRUMMOND DC, GREISER U et al.: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. (2003) 63(12):3154-3161.
   PubMed Web of Science ®Google Scholar
• GRANA C, CHINOL M, ROBERTSON C et al.: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer (2002) 86(2):207-212.
   PubMed Web of Science ®Google Scholar
• PAGANELLI G, GRANA C, CHINOL M et al.: Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. (1999) 26(4):348-357.
   PubMedGoogle Scholar
• DI GAETANO N, CITTERA E, NOTA R et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. (2003) 171(3):1581-1587.
   PubMed Web of Science ®Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6(4):443-446.
   PubMed Web of Science ®Google Scholar
• SAMPSON JH, CROTTY LE, LEE S et al.: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. USA (2000) 97(13):7503-7508.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, BELSER PH, ATKINSON BF et al.: Monoclonal antibody-dependent, cell-mediated cytotoxicity against human malignant gliomas. Neurosurgery (1990) 27(1):97-102.
   PubMed Web of Science ®Google Scholar
• CLAYTON AJ, DANSON S, JOLLY S et al.: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer (2004) 91(4):639-643.
   PubMed Web of Science ®Google Scholar
• BENDELL JC, DOMCHEK SM, BURSTEIN HJ et al.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 97(12):2972-2977.
   PubMed Web of Science ®Google Scholar
• SHAPIRO WR, CARPENTER SP, ROBERTS K, SHAN JS: 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther. (2006) 6(5):539-545.
   Google Scholar
• PATEL SJ, SHAPIRO WR, LASKE DW et al.: Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery (2005) 56(6):1243-1252 (Discussion 1252-1253).
   PubMed Web of Science ®Google Scholar
• YANG W, BARTH RF, WU G et al.: Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin. Cancer Res. (2005) 11(1):341-350.
   Google Scholar
• LEE YS, BULLARD DE, WIKSTRAND CJ, ZALUTSKY MR, MUHLBAIER LH, BIGNER DD: Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res. (1987) 47(7):1941-1946.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK J, DESJARDINS A, VREDENBURGH JJ et al.: Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF) and temozolomide: study of cases. J. Clin. Oncol. (2006) 24(Suppl. 18S):11522 (Abstract).
   Google Scholar
• VREDENBURGH JJ, DESJARDINS A, HERNDON JE et al.: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J. Clin. Oncol. (2006) 24(Suppl. 18S):1506 (Abstract).
   Google Scholar
• KIM KJ, WANG L, SU YC et al.: Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. (2006) 12(4):1292-1298.
   Google Scholar
• BRADY LW, MIYAMOTO C, WOO DV et al.: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. (1992) 22(1):225-230.
   PubMed Web of Science ®Google Scholar
• BENDER H, EMRICH JG, ESHELMAN J et al.: Enhancement of monoclonal antibody efficacy: the effect of external beam radiation. Hybridoma (1995) 14(2):129-134.
   PubMed Web of Science ®Google Scholar
• DEMATTOS RB, BALES KR, CUMMINS DJ, DODART JC, PAUL SM, HOLTZMAN DM: Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer′s disease. Proc. Natl. Acad. Sci. USA (2001) 98(15):8850-8855.
   PubMed Web of Science ®Google Scholar
• ST CROIX B, RAGO C, VELCULESCU V et al.: Genes expressed in human tumor endothelium. Science (2000) 289(5482):1197-202.
   PubMed Web of Science ®Google Scholar
• MADDEN SL, COOK BP, NACHT M et al.: Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. (2004) 165(2):601-608.
   PubMed Web of Science ®Google Scholar
• BOURDON MA, WIKSTRAND CJ, FURTHMAYR H, MATTHEWS TJ, BIGNER DD: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. (1983) 43(6):2796-2805.
   PubMed Web of Science ®Google Scholar
• LEINS A, RIVA P, LINDSTEDT R, DAVIDOFF MS, MEHRAEIN P, WEIS S: Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer (2003) 98(11):2430-2439.
   PubMed Web of Science ®Google Scholar
• HEROLD-MENDE C, MUELLER MM, BONSANTO MM, SCHMITT HP, KUNZE S, STEINER HH: Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer (2002) 98(3):362-369.
   PubMed Web of Science ®Google Scholar
• HIGUCHI M, OHNISHI T, ARITA N, HIRAGA S, HAYAKAWA T: Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol. (Berl.) (1993) 85(5):481-487.
   PubMed Web of Science ®Google Scholar
• LEE Y, BULLARD DE, HUMPHREY PA et al.: Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. (1988) 48(10):2904-2910.
   PubMed Web of Science ®Google Scholar
• ZALUTSKY MR, MOSELEY RP, COAKHAM HB, COLEMAN RE, BIGNER DD: Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. (1989) 49(10):2807-2813.
   PubMed Web of Science ®Google Scholar
• BIGNER DD, BROWN MT, FRIEDMAN AH et al.: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. (1998) 16(6):2202-2212.
   Google Scholar
• REARDON DA, AKABANI G, COLEMAN RE et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. (2006) 24(1):115-122.
   Google Scholar
• REARDON DA, QUINN JA, AKABANI G et al.: Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J. Nucl. Med. (2006) 47(6):912-918.
   PubMed Web of Science ®Google Scholar
• RIVA P, FRANCESCHI G, FRATTARELLI M et al.: 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-Phase I and II study. Acta Oncol. (1999) 38(3):351-359.
   PubMed Web of Science ®Google Scholar
• HEDBERG KM, MAHESPARAN R, READ TA et al.: The glioma-associated gangliosides 3′-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains. Neuropathol. Appl. Neurobiol. (2001) 27(6):451-464.
   Web of Science ®Google Scholar
• WIKSTRAND CJ, FREDMAN P, SVENNERHOLM L, BIGNER DD: Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog. Brain Res. (1994) 101:213-223.
   Google Scholar
• ARBIT E, CHEUNG NK, YEH SD et al.: Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. Eur. J. Nucl. Med. (1995) 22(5):419-426.
   PubMedGoogle Scholar
• DOHI T, NAKAMURA K, HANAI N, TAOMOTO K, OSHIMA M: Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors. Anticancer Res. (1994) 14(6B):2577-2581.
   PubMed Web of Science ®Google Scholar
• TSUZUKI T, IZUMOTO S, OHNISHI T, HIRAGA S, ARITA N, HAYAKAWA T: Neural cell adhesion molecule L1 in gliomas: correlation with TGF-β and p53. J. Clin. Pathol. (1998) 51(1):13-17.
   Google Scholar
• PAPANASTASSIOU V, PIZER BL, COAKHAM HB, BULLIMORE J, ZANANIRI T, KEMSHEAD JT: Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br. J. Cancer (1993) 67(1):144-151.
   PubMed Web of Science ®Google Scholar
• HJORTLAND GO, GARMAN-VIK SS, JUELL S et al.: Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J. Neurosurg. (2004) 100(2):320-327.
   PubMed Web of Science ®Google Scholar
• HALATSCH ME, SCHMIDT U, BEHNKE-MURSCH J, UNTERBERG A, WIRTZ CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. (2006) 32(2):74-89.
   Google Scholar
• OLIVEIRA S, VAN BERGEN EN HENEGOUWEN PM, STORM G, SCHIFFELERS RM: Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin. Biol. Ther. (2006) 6(6):605-617.
   Google Scholar
• BENJAMIN R, CAPPARELLA J, BROWN A: Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. (2003) 9(2):82-90.
   PubMed Web of Science ®Google Scholar
• SHINOJIMA N, TADA K, SHIRAISHI S et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. (2003) 63(20):6962-6970.
   PubMed Web of Science ®Google Scholar
• MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353(19):2012-2024.
   PubMed Web of Science ®Google Scholar
• ELLER JL, LONGO SL, HICKLIN DJ, CANUTE GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery (2002) 51(4):1005-1013 (Discussion 1013-1014).
   PubMed Web of Science ®Google Scholar
• FAILLOT T, MAGDELENAT H, MADY E et al. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery (1996) 39(3):478-483.
   PubMed Web of Science ®Google Scholar
• EMRICH JG, BRADY LW, QUANG TS et al.: Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol. (2002) 25(6):541-546.
   Web of Science ®Google Scholar
• CASACO A, LOPEZ G, FERNANDEZ R et al.: Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-re. Proc. Am. Soc. Clin. Oncol. (2004) 22(14S):2530.
   Google Scholar
• RAMOS TC, FIGUEREDO J, CATALA M et al.: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a Phase I/II trial. Cancer Biol. Ther. (2006) 5(4):375-379.
   PubMed Web of Science ®Google Scholar
• BODE U, BUCHEN S, JANSSEN T et al.: Results of a Phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J. Clin. Oncol. (2006) 24(Suppl. 18S):1522 (Abstract).
   Google Scholar
• PEDERSEN MW, MELTORN M, DAMSTRUP L, POULSEN HS: The type III epidermal growth factor receptor mutation. biological significance and potential target for anti-cancer therapy. Ann. Oncol. (2001) 12(6):745-760.
   PubMed Web of Science ®Google Scholar
• KONDO S, MIYATAKE S, IWASAKI K et al.: Human glioma-specific antigens detected by monoclonal antibodies. Neurosurgery (1992) 30(4):506-511.
   PubMed Web of Science ®Google Scholar
• KUAN CT, WIKSTRAND CJ, BIGNER DD: EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. (2000) 17(2):71-78.
   PubMedGoogle Scholar
• NISHIKAWA R, JI XD, HARMON RC et al.: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA (1994) 91(16):7727-7731.
   PubMed Web of Science ®Google Scholar
• PERERA RM, NARITA Y, FURNARI FB et al.: Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. (2005) 11(17):6390-6399.
   Google Scholar
• LUWOR RB, JOHNS TG, MURONE C et al.: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. (2001) 61(14):5355-5361.
   PubMed Web of Science ®Google Scholar
• SAMPSON JH, AKABANI G, ARCHER GE et al.: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. (2003) 65(1):27-35.
   PubMed Web of Science ®Google Scholar
• TAKASU S, TAKAHASHI T, OKAMOTO S et al.: Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J. Neurooncol. (2003) 63(3):247-256.
   PubMed Web of Science ®Google Scholar
• CARDONES AR, BANEZ LL: VEGF inhibitors in cancer therapy. Curr. Pharm. Des. (2006) 12(3):387-394.
   Web of Science ®Google Scholar
• PUROW B, FINE HA: Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest. (2004) 22(4):577-587.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(Suppl. 14S):3702.
   Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
   Google Scholar
• POPE WB, LAI A, NGHIEMPHU P, MISCHEL P, CLOUGHESY TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology (2006) 66(8):1258-1260.
   PubMed Web of Science ®Google Scholar
• HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23(5):1011-1027.
   Google Scholar
• JAIN RK: Molecular regulation of vessel maturation. Nat. Med. (2003) 9(6):685-693.
   PubMed Web of Science ®Google Scholar
• LAMSZUS K, KUNKEL P, WESTPHAL M: Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. (2003) 88:169-177.
   PubMedGoogle Scholar
• KUNKEL P, ULBRICHT U, BOHLEN P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. (2001) 61(18):6624-6628.
   PubMed Web of Science ®Google Scholar
• KOZIN SV, BOUCHER Y, HICKLIN DJ, BOHLEN P, JAIN RK, SUIT HD: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. (2001) 61(1):39-44.
   PubMed Web of Science ®Google Scholar
• ABOUNADER R, RANGANATHAN S, LAL B et al.: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. (1999) 91(18):1548-1556.
   PubMed Web of Science ®Google Scholar
• BOWERS DC, FAN S, WALTER KA et al.: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. (2000) 60(15):4277-4283.
   PubMed Web of Science ®Google Scholar
• BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VANDE WOUDE GF: Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. (2003) 4(12):915-925.
   PubMed Web of Science ®Google Scholar
• LAMSZUS K, SCHMIDT NO, JIN L et al.: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int. J. Cancer (1998) 75(1):19-28.
   PubMed Web of Science ®Google Scholar
• ABOUNADER R, LATERRA J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol. (2005) 7(4):436-451.
   PubMed Web of Science ®Google Scholar
• CAO B, SU Y, OSKARSSON M et al.: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98(13):7443-7448.
   PubMed Web of Science ®Google Scholar
• BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI JA, FUKUMOTO M, KOZAI Y et al.: Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett. (1991) 288(1-2):65-71.
   PubMed Web of Science ®Google Scholar
• BREYER R, HUSSEIN S, RADU DL et al.: Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J. Neurosurg. (2000) 92(1):140-149.
   PubMed Web of Science ®Google Scholar
• COPE DA, DEWHIRST MW, FRIEDMAN HS, BIGNER DD, ZALUTSKY MR: Enhanced delivery of a monoclonal antibody F(ab′)2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res. (1990) 50(6):1803-1809.
   PubMed Web of Science ®Google Scholar
• BENDER H, TAKAHASHI H, ADACHI K et al.: Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res. (1992) 52(1):121-126.
   PubMed Web of Science ®Google Scholar
• LAMSZUS K, BROCKMANN MA, ECKERICH C et al.: Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. (2005) 11(13):4934-4940.
   Google Scholar
• ZALUTSKY MR: Targeted radiotherapy of brain tumours. Br. J. Cancer (2004) 90(8):1469-1473.
   PubMed Web of Science ®Google Scholar
• RUBENSTEIN JL, KIM J, OZAWA T et al.: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2000) 2(4):306-314.
   PubMed Web of Science ®Google Scholar
• KIM KJ, WANG L, SU Y et al.: Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft. Proc. Am. Assoc. Cancer Res. (2006) 47:267.
   Google Scholar
• CROMBET T, TORRES O, RODRIGUEZ V et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma (2001) 20(2):131-136.
   PubMed Web of Science ®Google Scholar
• LASKE DW, MURASZKO KM, OLDFIELD EH et al.: Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery (1997) 41(5):1039-1049 (Discussion 1049-1051).
   PubMed Web of Science ®Google Scholar
• RIVA P, FRANCESCHI G, FRATTARELLI M et al.: Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin. Cancer Res. (1999) 5(Suppl. 10):3275s-3280s.
   Google Scholar